FDA approves Teva’s QNASL with Bespak Dose Counter
Consort Medical plc (LSE: CSRT), today is pleased to announce that the FDA has approved the first product to use Bespak’s proprietary Integrated Dose Counter (IDC).
The IDC is being used with Teva’s QNASL Nasal Aerosol for the treatment of nasal symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and adolescents 12 years of age and older. The product is now available by prescription and is the first marketed nonaqueous or “dry” nasal aerosol in a product category that reports annual sales of $2.5 billion. QNASL is delivered as a once-daily, pressurized, HFA-propelled nonaqueous aerosol that is environmentally friendly and offers a built-in dose counter.
Bespak has been developing its IDC for a number of years in response to an important patient and compliance need to let patients know if their device contains sufficient drug and to indicate when they need to seek a further prescription. It provides patients with a reliable, easy to read indication of how many doses are left inside the canister in line with FDA guidance. This programme has been launched on schedule in 2012, and has previously been identified on the product development pipeline as IDC220.
Jon Glenn, Chief Executive of Consort Medical, said; “we are very pleased to announce that the FDA has approved the use of our IDC with Teva’s QNASL®, making this our first commercially marketed Integrated Dose Counter. We are also delighted to support Teva in their launch of this important new treatment for a debilitating condition.”
For enquiries, please contact:
Consort Medical plc
Jonathan Glenn, Chief Executive: Tel: +44 (0) 1442 867920
Toby Woolrych, Group Finance Director: Tel: +44 (0) 1442 867920
Jon Coles/Justine McIlroy: Tel: +44 (0) 20 7404 5959
Consort Medical plc is a leader in medical devices for inhaled drug delivery, self-injection and anaesthesia. The Group develops drug delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings in hospitals.
Consort Medical’s Bespak division develops and manufactures drug delivery devices and diagnostic disposable devices, including metered dose inhaler valves, actuators, compliance aids, dry powder devices, and autoinjectors. The King Systems division develops and manufactures disposable devices for anaesthetists and emergency medical practitioners, including video laryngoscopes, disposable facemasks, breathing circuits and laryngeal tubes. The Group has facilities in King’s Lynn, Cambridge, Nelson and Hemel Hempstead in the UK, and Indianapolis, Indiana and Kent, Ohio in the US. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT).